EVKEEZA

US FDA expands use of Regeneron's cholesterol drug in young children

The drug, Evkeeza, was approved in February 2021 as an additional treatment with other lipid-lowering therapies, for patients aged 12 years and above with homozygous familial hypercholesterolemia (HoFH).